Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose series and MenB-4C was licensed as two-dose series. Evidence of benefits and harms were reviewed in accordance with GRADE methods (1). The primary policy question was “Should MenB vaccines be administered routinely to all adolescents and young adults (including college students)?”